Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: Comparison of an antigenemia assay and quantitative real-time polymerase chain reaction

Bone Marrow Transplantation

Volumn 29, Issue 7, 2002, Pages 599-606

  Yakushiji, K ^a   Gondo, H ^b   Kamezaki, K ^b   Shigematsu, K ^c   Hayashi, S ^c   Kuroiwa, M ^d   Taniguchi, S ^d   Ohno, Y ^e   Takase, K ^b   Numata, A ^b   Aoki, K ^b   Kato, K ^b   Nagafuji, K ^b   Shimoda, K ^b   Okamura, T ^a,b   Kinukawa, N ^f   Kasuga, N ^g   Sata, M ^a   Harada, M ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c HARASANSHIN HOSPITAL   (Japan)

^d HAMANOMACHI HOSPITAL   (Japan)

^e Kitakyushu Municipal Hospital   (Japan)

^f KYUSHU UNIVERSITY HOSPITAL   (Japan)

^g OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antigenemia; Cytomegalovirus; Quantitative real time PCR; Stem cell transplantation

Indexed keywords

ACICLOVIR; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GANCICLOVIR; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; TACROLIMUS; THIOTEPA; VIRUS ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ALLOTRANSPLANTATION; ARTICLE; COLITIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DONOR; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNOASSAY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECIPIENT; SENSITIVITY AND SPECIFICITY; SIBLING; VIRUS DETECTION; VIRUS REACTIVATION;

ADOLESCENT; ADULT; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; COLITIS; COMPUTER SYSTEMS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NUCLEAR FAMILY; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; VIREMIA; VIRUS ACTIVATION;

EID: 85047700366     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703513     Document Type: Article

References (29)

1. Cytomegalovirus infection
2. Cytomegalovirus pp65 antigenemia- guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
3. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes
4. Cytomegalovirus antigenemia
5. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation
6. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation
7. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors
8. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: A single-center experience in Japan
9. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
10. Monitoring of cytomegalovirus infection and disease in bone marrow recipients by reverse transcription-PCR and comparison with PCR and blood and urine cultures
11. Monitoring of CMV infection: A comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation
12. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation
13. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
14. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients
15. Time course analysis of semi-quantitative PCR and antigenaemia assay for prevention of cytomegalovirus disease after bone marrow transplantation
16. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: Clinical utility of the prototype Amplicor CMV Monitor test in transplant recipients
17. Application of viralload kinetics to identify patients who develop cytomegalovirus disease after transplantation
18. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation
19. Bone marrow transplantation
20. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease
21. Definitions of cytomegalovirus infection and disease
22. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients
23. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for pre-emptive therapy in bone marrow transplant recipients
24. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation
25. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
26. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants
27. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem cell transplantation: A single-center experience
28. Risk-adapted preemptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation
29. Intestinal cytomegalovirus disease in immunocompromised patients may be ruled out by search for cytomegalovirus DNA in stool samples